Nanjing Well Pharmaceutical Group Co.,Ltd. (SHA:603351)

SHA:603351 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	1,307	1,287	1,152	1,103	1,032	729.59
Other Revenue	9.94	9.94	4.21	8.36	10.24	6.47
Revenue	1,317	1,297	1,156	1,111	1,042	736.06
Revenue Growth (YoY)	6.25%	12.19%	4.04%	6.59%	41.60%	-16.43%
Cost of Revenue	953.14	938.49	842.97	810.66	762.68	513.45
Gross Profit	363.5	358.26	312.87	300.36	279.63	222.62
Selling, General & Admin	116.11	115.84	121.5	126.32	107.53	72.8
Research & Development	73.99	71.56	55.64	53.87	40.73	34.83
Other Operating Expenses	1.18	1.25	3.23	7.6	6.77	5.76
Operating Expenses	191.62	188.99	180.67	183.31	157.17	114.63
Operating Income	171.88	169.27	132.2	117.04	122.46	107.99
Interest Expense	-13.84	-13.84	-15.25	-12.48	-7.04	-5
Interest & Investment Income	0.93	0.93	0.78	0.63	1.47	8.5
Currency Exchange Gain (Loss)	1.54	1.54	0.53	2.48	-0.51	-0.92
Other Non Operating Income (Expenses)	-1.02	-0.48	-0.03	-0.2	-0.71	0.03
EBT Excluding Unusual Items	159.49	157.42	118.23	107.47	115.67	110.59
Gain (Loss) on Sale of Investments	12.05	12	1.44	-0.11	1.7	4.24
Gain (Loss) on Sale of Assets	-0.16	-0.17	-0.18	-0.1	-0.18	-0.83
Other Unusual Items	2.87	2.87	1.95	5.59	1.54	4.28
Pretax Income	174.25	172.13	121.44	112.85	118.74	118.28
Income Tax Expense	26.8	26.93	12.33	18.42	18.59	17.83
Earnings From Continuing Operations	147.46	145.21	109.11	94.43	100.15	100.45
Net Income to Company	147.46	145.21	109.11	94.43	100.15	100.45
Minority Interest in Earnings	0.95	1.22	3.08	0.6	1.22	-
Net Income	148.41	146.42	112.2	95.03	101.37	100.45
Net Income to Common	148.41	146.42	112.2	95.03	101.37	100.45
Net Income Growth	23.17%	30.50%	18.07%	-6.26%	0.92%	-21.59%
Shares Outstanding (Basic)	136	136	135	132	133	130
Shares Outstanding (Diluted)	136	136	135	134	133	130
Shares Change (YoY)	0.46%	0.29%	1.00%	0.35%	2.25%	1.83%
EPS (Basic)	1.09	1.08	0.83	0.72	0.76	0.77
EPS (Diluted)	1.09	1.08	0.83	0.71	0.76	0.77
EPS Growth	22.61%	30.12%	16.90%	-6.58%	-1.30%	-23.00%
Free Cash Flow	156.98	170.34	47.17	-124.91	-247.16	-189.13
Free Cash Flow Per Share	1.15	1.26	0.35	-0.93	-1.85	-1.45
Dividend Per Share	0.400	0.400	0.300	0.280	0.300	0.300
Dividend Growth	33.33%	33.33%	7.14%	-6.67%	-	-6.66%
Gross Margin	27.61%	27.63%	27.07%	27.03%	26.83%	30.24%
Operating Margin	13.05%	13.05%	11.44%	10.54%	11.75%	14.67%
Profit Margin	11.27%	11.29%	9.71%	8.55%	9.73%	13.65%
Free Cash Flow Margin	11.92%	13.14%	4.08%	-11.24%	-23.71%	-25.70%
EBITDA	288.36	276.06	200.26	180.62	162.12	142.33
EBITDA Margin	21.90%	21.29%	17.33%	16.26%	15.55%	19.34%
D&A For EBITDA	116.47	106.79	68.06	63.58	39.66	34.34
EBIT	171.88	169.27	132.2	117.04	122.46	107.99
EBIT Margin	13.05%	13.05%	11.44%	10.54%	11.75%	14.67%
Effective Tax Rate	15.38%	15.64%	10.15%	16.32%	15.65%	15.08%
Revenue as Reported	1,297	1,297	1,156	1,111	1,042	736.06
Advertising Expenses	-	1.09	1.82	0.39	0.61	0.7

Source: S&P Global Market Intelligence. Standard template. Financial Sources.